Drug Type Autologous CAR-T |
Synonyms Anti-CD7 CAR-T- cell therapy (PersonGen Biomedicine), Autologous CD7CART cells PersonGen Biotherapeutics, PA3 17 + [1] |
Target |
Action inhibitors |
Mechanism CD7 inhibitors(T-cell antigen CD7 inhibitors), Immunologic cytotoxicity, T lymphocyte replacements |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
RegulationOrphan Drug (United States), Orphan Drug (European Union) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
T-Cell Lymphoma | Phase 2 | China | 05 Aug 2021 | |
Mixed phenotype acute leukemia | Phase 2 | China | 01 Jun 2021 | |
T-cell Acute Lymphoblastic Leukemia/Lymphoma | Phase 2 | China | 01 Jun 2021 | |
CD7 Positive Neoplasms | Phase 1 | China | 21 Feb 2022 | |
ALK-positive anaplastic large cell lymphoma | Phase 1 | China | 24 Nov 2020 | |
Anaplastic Large-Cell Lymphoma | Phase 1 | China | 24 Nov 2020 | |
CD7 positive Hematologic Neoplasms | Phase 1 | China | 24 Nov 2020 | |
Enteropathy-Associated T-Cell Lymphoma | Phase 1 | China | 24 Nov 2020 | |
Immunoblastic Lymphadenopathy | Phase 1 | China | 24 Nov 2020 | |
Peripheral T-Cell Lymphoma | Phase 1 | China | 24 Nov 2020 |
Phase 1 | 13 | PA3-17 Injection | kuydvrnrnp(ofwxsnxvkd) = Cytokine release syndrome (CRS) incidence was 84.6% (G3:23.1%, no G4) owgynqrmnj (mjbvtlrulp ) View more | Positive | 14 May 2025 | ||
NCT05170568 (ASCO2024) Manual | Phase 1 | 12 | PA3-17 Injection 0.5×10^6 CAR-T/kg | kxqldrnhzu(sqlrqoatsf) = None vtyoqhfuil (ypvaxbplxd ) View more | Positive | 24 May 2024 | |
Phase 1 | 9 | DL: 0.5×10^6 CAR-T/kg | ctcbwaouaa(xebwizldjz) = hpvfjqvzuu wwphgnglrw (agfxyfjvzr ) | - | 10 Dec 2023 | ||
Phase 1 | 11 | irnvtajgmd(ulybzdnqpu) = 患者均出现了CRS(1-2级, n=10;4级, n=1) zyyouojecl (ovsvgayrbe ) View more | - | 21 Sep 2022 | |||
Phase 1 | T-cell Acute Lymphoblastic Leukemia/Lymphoma CD7 Positive | 8 | vtwbgktvew(wtanjlsfnp) = xsthuzfadj pbhenbhjjg (miciqtppsl ) View more | Positive | 01 Jul 2022 |